Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 21;41:149. doi: 10.1186/s13046-022-02362-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — CDK16 is highly expressed in TNBC and is correlated with poor clinical outcomes. A-D Clinical relevance analysis of CDK16 using data from TCGA breast cancer dataset. Shown are CDK16 mRNA expression profile in different molecular subtypes of breast cancer (A) and Kaplan-Meier curves of OS (B), PFS (C), and DFS (D) of breast cancer patients stratified by CDK16 mRNA levels. E-F Clinical relevance analysis of CDK16 using data from combined databases of METABRIC, Nature 2012 and Nature Communication 2016. Shown are CDK16 mRNA expression pattern (E) and overall survival analysis (F). G CDK16 mRNA expression level in normal breast tissues and in TNBC tissues of patients in GSE76250 dataset. H-I CDK16 protein expression in normal and breast cancer tissues (H), and in distinct breast cancer subtypes (I) of CPTAC samples. J Representative immunohistochemical staining images of TNBC and adjacent tissues elucidated by CDK16 antibody (left panel, scale bar: 50 μm) and statistical analysis of immunohistochemical staining intensity (right panel). The commercial tissue microarray used in (J) was from Zhongke Guanghua (Xi’an) Intelligent Biotechnology Co., Ltd. K Immunoblot analysis of CDK16 protein expression in clinical non-cancerous (N) and TNBC (T) samples collected from Zhongnan Hospital of Wuhan University. Error bars represent mean ± SD. p values were obtained by log rank test (B, C, D, and F) or two-tailed Student’s t-test (others). All *p < 0.05, ** p < 0.01, ***p < 0.001, **** p < 0.0001, ns, not significant